Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:A61K39/12

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/136060A PEPTIDE-MHC-I-ANTIBODY FUSION PROTEIN FOR THERAPEUTIC USE IN A PATIENT WITH AMPLIFIED IMMUNE RESPONSE
WO 02.07.2020
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Appl.No PCT/EP2019/086072 Applicant F. HOFFMANN-LA ROCHE AG Inventor KNOETGEN, Hendrik
The present invention relates to a peptide-MHC-I-antibody fusion protein for use as a therapeutic medicament administered to a patient, wherein a cellular cytotoxic immune response towards the virus-derived peptide has been amplified in the patient. The therapeutic medicament may be used in a kit of parts and administered in combination with an amplifying medicament and optionally an inducing medicament. The inducing medicament and the amplifying medicament may be for use in a method of making a patient susceptible for a treatment with the peptide-MHC-I-antibody fusion protein.The medicament(s) may be used for the treatment of diseases, such as cancer or a viral infection.
2.WO/2020/132770VIRUS-LIKE PARTICLES (VLP) OF THE INFECTIOUS SALMON ANEMIA VIRUS (ISAV) THAT COMPRISE MATRIX PROTEIN AND ONE OR MORE ANTIGENIC PROTEINS OF THE VIRUS; PRODUCTION METHOD, COMPOSITION, VACCINE AND FISH FEED; RECOMBINANT BACULOVIRUS; AND VACCINATION KIT; AND
WO 02.07.2020
Int.Class A61K 39/145
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
145Orthomyxoviridae, e.g. influenza virus
Appl.No PCT/CL2019/050152 Applicant UNIVERSIDAD DE SANTIAGO DE CHILE Inventor CORTEZ SAN MARTIN, Marcelo
The present invention relates to the field of veterinary medicine, particularly vaccines and animal health in aquaculture. The invention concerns virus-like particles (VLP) formed by molecular complexes comprising proteins of infectious salmon anemia virus (ISAV), the genes of which are expressed in insect cells, and which are used as vaccines together with induced cellular bodies as adjuvants. The invention also concerns pharmaceutical compositions, vaccines, fish feed and a kit, which comprise the VLP, and the use of the VLP to prepare drugs.
3.WO/2020/134682PHARMACEUTICAL PREPARATION FOR TREATING HEPATITIS B, PREPARATION METHOD THEREFOR AND USE THEREOF
WO 02.07.2020
Int.Class A61K 39/39
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
39characterised by the immunostimulating additives, e.g. chemical adjuvants
Appl.No PCT/CN2019/118778 Applicant JIANGSU THERAVAC BIO-PHARMACEUTICAL CO., LTD. Inventor LI, Jianqiang
Disclosed are a pharmaceutical preparation for treating hepatitis B, a preparation method therefor and use thereof. The pharmaceutical preparation comprises a hepatitis B surface antigen solution, further comprises a hepatitis B core antigen solution, and also comprises an oligodeoxynucleotide solution. The pharmaceutical preparation is sugar-free, has simple composition and good antigen stability, does not have side effects caused by an aluminum adjuvant, and thus has excellent preservation effect in long-term stability experiment.
4.WO/2020/139963UNIDIRECTIONAL PRESENTATION OF MEMBRANE PROTEINS IN NANOPARTICLE-SUPPORTED LIPOSOMES
WO 02.07.2020
Int.Class A61K 9/127
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
10Dispersions; Emulsions
127Liposomes
Appl.No PCT/US2019/068601 Applicant PRESIDENT AND FELLOWS OF HARVARD COLLEGE Inventor CHOU, James
Presentation of membrane proteins to host immune systems has been a challenging problem due to complexity arising from the poor in vivo stability of the membrane-mimetic media often used for solubilizing the membrane proteins. The Inventors report the use of functionalized, biocompatible nanoparticles as substrates to guide the formation of proteoliposomes that can present many copies of membrane proteins in a unidirectional manner. The approach was demonstrated to present the membrane-proximal region of the HIV-1 envelope glycoprotein. These nanoparticle-supported liposomes are broadly applicable as membrane antigen vehicles for inducing host immune responses. In some instances, the technology supports generation of antibodies that do not generate an immunogenic response in comparison to conventional protein presentation (i.e., liposome).
5.WO/2020/136210METHOD FOR THE EXPANSION OF HPV IMMUNOGEN SPECIFIC T-CELLS
WO 02.07.2020
Int.Class A61K 35/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
Appl.No PCT/EP2019/087030 Applicant TCER AB Inventor GRONLUND, Hans
The present invention provides a method for the expansion of HPV immunogen specific Tcells, comprising the steps of: i.providing a phagocytosable particle comprising a core and a human papillomavirus (HPV)immunogen tightly associated to the core; wherein the HPV immunogen has an amino acid sequence that corresponds to the amino acid sequence of a HPV protein, or has an amino acid sequence that corresponds to an amino acid sequence of a part of a HPV protein; ii.providing APCs; iii.contacting the phagocytosable particle comprising a core and a HPV immunogen with the APCs from step ii in vitro, and under conditions allowing phagocytosis of the HPV immunogen by the APCs; iv.providing T-cells that have been harvested from asubject; v.contacting the T-cells with the APCs from step iii) in vitro, and under conditions allowing specific activation of HPV immunogen specific T-cells. The invention further provides an expanded population of therapeutically useful T-cells and their use in the treatment or prevention of cancer, particularly HPV positive cancers.
6.WO/2020/136220RECOMBINANT VIRUSES AND THE USES THEREOF
WO 02.07.2020
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Appl.No PCT/EP2019/087042 Applicant CEVA SANTE ANIMALE Inventor SASAKI, Kenta
The present invention relates recombinant viruses and the uses thereof. More particularly, the invention relates to novel recombinant Marek's disease viruses encoding polypeptide(s) of interest, and their use to express or deliver such polypeptides to animals, particularly poultry. The invention is particularly suited to vaccinate poultry against avian pathogens.
7.WO/2020/136282NOROVIRUS VACCINES
WO 02.07.2020
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Appl.No PCT/EP2019/087160 Applicant THEMIS BIOSCIENCE GMBH Inventor TAUBER, Erich
The present invention provides immunogenic compositions, nucleic acid molecules and VLPs suitable as Norovirus vaccine candidates. Further provided are host cells for producing the biological material as well as methods for producing and/or purifying the immunogenic compositions and VLPs. Further provided is an immunogenic composition for use in methods of preventing/treating a Norovirus infection in a subject.
8.WO/2020/136683ADAPTATION OF ENTEROVIRUS TO VERO CELLS AND VACCINE FORMULATIONS THEREOF
WO 02.07.2020
Int.Class A61K 39/125
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
125Picornaviridae, e.g. calicivirus
Appl.No PCT/IN2019/050960 Applicant BHARAT BIOTECH INTERNATIONAL LIMITED Inventor RAYCHOUDHURI, Amit
The present invention discloses Enterovirus D68 adapted to propagate to high titers in Vero cells and method of adaptation thereof. The present invention also discloses suitable vaccine composition comprising inactivated Enterovirus D68 antigen.
9.WO/2020/133817IMMUNOLOGIC ADJUVANT COMPOSITION AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
WO 02.07.2020
Int.Class A61K 39/39
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
39characterised by the immunostimulating additives, e.g. chemical adjuvants
Appl.No PCT/CN2019/083106 Applicant LUOYANG SEIWEI BIOTECHNOLOGIES CO., LTD. Inventor TIAN, Kegong
The present invention provides an adjuvant composition, containing 0.2%-0.5%w/v of Carbomer, 0.1%-0.5% w/v of lecithin and 0.03%-0.2%w/v of ginsenoside. The adjuvant composition of the present invention not only guarantees vaccines to be clarified and/or stabilized for a long time but also effectively stimulates inactivated antigens and subunit antigens in the vaccines to generate high-titer antibody for immune protection. Inactivated vaccines or subunit vaccines prepared by the adjuvant composition according to the present invention can be used as diluents for freeze-dried live-virus antigens, and have no toxic action on live-virus antigens.
10.WO/2020/138761CHIMERIC VIRUS OF PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS, AND VACCINE USING SAME
WO 02.07.2020
Int.Class C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
Appl.No PCT/KR2019/017319 Applicant BIOPOA, INC. Inventor CHO, Sun-Hee
The present invention relates to a chimeric virus of porcine reproductive and respiratory syndrome (PRRS) virus, the chimeric virus being usable as a vaccine. A PRRSV chimeric virus of the present invention is more attenuated than the parent strain thereof, and thus promotes the secretion of neutralizing antibodies while having low pathogenicity and high stability, thereby being usable as a vaccine in the effective prevention and treatment of PRRS diseases.